Semax: Research Overview

Semax is a synthetic heptapeptide analogue of the adrenocorticotropic hormone (ACTH) fragment 4–7, developed in Russia during the 1980s. Unlike ACTH itself, Semax lacks hormonal activity at the adrenal axis but retains the neurological profile of its parent sequence. It has been studied extensively in preclinical models for its effects on cognition, neuroplasticity, and neuroprotection. Semax gained particular attention for its ability to influence BDNF (brain-derived neurotrophic factor) levels and its resistance to rapid enzymatic degradation.

Mechanism of Action

Semax appears to work through multiple central nervous system pathways. Research indicates it stimulates the release of BDNF and nerve growth factor (NGF) in the brain, which are critical for neuronal survival and synaptic plasticity. It also influences the expression of genes involved in serotonin, dopamine, and enkephalin metabolism. Some studies have documented Semax’s ability to modulate the activity of key enzymes involved in neurotransmitter breakdown. Its intranasal bioavailability has made it a particularly interesting compound for CNS-focused research protocols.

Key Research Areas

• Neuroprotection Models: Animal studies have examined Semax in models of ischemic stroke and traumatic brain injury, with data suggesting reduced neuronal death and improved functional recovery markers.
• Cognitive Performance: Rodent studies using maze-based learning tasks have reported enhanced memory consolidation and attention in Semax-treated subjects compared to controls.
• Neurotrophin Upregulation: Research has documented significant increases in BDNF and NGF expression following Semax administration, with interest in applications involving neurodegenerative disease models.
• Attention and Focus Research: Some preclinical models have explored Semax in the context of attention deficit and hyperactivity parameters, with results suggesting modulation of dopaminergic tone.

Research Applications

Semax is used in neuroscience research settings, particularly in studies examining neuroplasticity, recovery from CNS injury, and cognitive function. Its intranasal route of administration in animal models is well-documented, and researchers have also used subcutaneous injection in some protocols. Given its BDNF-stimulating properties, it is sometimes paired with behavioral testing batteries designed to assess hippocampal-dependent learning and memory. It is also used as a reference compound in studies comparing nootropic peptides.

Storage and Handling

Semax is provided in lyophilized powder form and should be stored at -20°C, away from moisture and light. Reconstitute with sterile bacteriostatic water for research use. Once in solution, refrigerate at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles. Standard aseptic technique applies during all preparation steps.

Available from Alpha Peptides US

Alpha Peptides US supplies Semax 10mg for use in qualified research applications. Suitable for neuroscience and cognitive research protocols.

This product is intended for laboratory research purposes only. It is not approved by the FDA and is not intended for human or veterinary use, diagnosis, treatment, or prevention of any condition.